TaiRx, Inc. (TPEX:6580)

Market Cap	2.24B -20.7%
Revenue (ttm)	15.46M +190.6%
Net Income	-141.99M
EPS	-1.29
Shares Out	110.69M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	118,556
Average Volume	112,862
Open	20.10
Previous Close	20.10
Day's Range	19.80 - 20.20
52-Week Range	17.40 - 31.80
Beta	0.22
RSI	32.36
Earnings Date	Apr 10, 2026

About TaiRx

TaiRx, Inc. focuses on the development and commercialization of therapeutics for the treatment of cancer and other diseases. The company’s products under development include CVM-1118, an oral anti-cancer drug that is Phase II clinical trial. Its pre-clinical products comprise TRX-920, an oral delivery formulation; and TRX-105, a molecule developed for treating and alleviating symptoms of various colitis. The company also offers Zelnite, a drug that helps in treatment of selenium deficiency; and focuses on development of the nodal diagnostic dev...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2011
• Employees: 29
• Stock Exchange: Taipei Exchange
• Ticker Symbol: 6580

Financial Performance

In 2024, TaiRx's revenue was 8.22 million, an increase of 61.79% compared to the previous year's 5.08 million. Losses were -138.84 million, -34.60% less than in 2023.